



مركز الكويت لمكافحة السرطان  
Kuwait Cancer Control Center

## Modified de Gramont Regimen + PANItumumab (Infusional 5-FU / Leucovorin / PANItumumab)



\* C O M B I N E D - 0 2 - 0 0 8 - G I \*



Ministry of Health

**Name:** \_\_\_\_\_ **File #:** \_\_\_\_\_ **Ht (cm):** \_\_\_\_\_  
**Nationality:** \_\_\_\_\_ **Civil ID:** \_\_\_\_\_ **Wt (Kg):** \_\_\_\_\_  
**Gender/Age:** \_\_\_\_\_ **DOB:** \_\_\_\_\_ **BSA (m<sup>2</sup>):** \_\_\_\_\_

**Indication(s):** Advanced stage colorectal cancer.

**Central line:**  Available  NA

**Allergies:**  NKA  Yes, specify; \_\_\_\_\_

**Parameters:** Initiate treatment only if ANC  $\geq$  1000; HB  $\geq$  80; Plt  $\geq$  100,000; CrCl  $>$  45 ml/min.

**Pre-treatment Medications:** (30-60 min before starting treatment)

Ondansetron 8 mg PO/IV  
Dexamethasone 10 mg PO/IV

### Standard Protocol:

DRUG	DOSE	ADMINISTRATION	DAYS
Leucovorin	200 mg/m <sup>2</sup>	IV In 250 mL NS over 2 hr.	D1
5-FU (bolus)	400 mg/m <sup>2</sup>	For IV In 250 mL NS over 15 min.	D1
5-FU (infusion)	2400 mg/m <sup>2</sup>	For outpatient: continuous infusion via 5-FU pump or For inpatient: IV in 1000 mL NS over 46 hr	D1, 2
PANItumumab	6 mg/kg	IV in 100 mL NS over 60 min. If the initial infusion is well tolerated, shorten second infusion to 30 min.	D1

**To be repeated every 2 week until disease progression or intolerable toxicity.**

**Special instructions:** The appropriate Dose Band INFUSOR for 5-FU will be applied accordingly.

### Treatment Description:

Cycle	Day	Date	Leucovorin	5-FU (bolus)	5-FU (inf.)	PANItumumab	Physician	Consultant
C# __	D1							
	D2		XXXXXXXX	XXXXXXXX		XXXXXXXX		

### Important Notes:

Reported grade 3/4 toxicities:  None  Hematological  Non-Hematological

If yes; Did it indicate hospitalization?  Yes  No

Did it indicate chemo-delay for  $\geq$  7 days?  Yes  No

Did it indicate dose reduction?  Yes  No

Did it indicate G-CSF support?  Yes  No